Osteoporosis in HIV Infected Postmenopausal Women

感染艾滋病毒的绝经后妇女的骨质疏松症

基本信息

  • 批准号:
    8299138
  • 负责人:
  • 金额:
    $ 72.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Postmenopausal HIV+ women are at increased risk of fracture and vulnerable to adverse effects of D deficiency, HIV infection and ART-related bone loss on bone strength. The increasing prevalence of HIV-infection on older minority women and the aging of the HIV-infected population make it critical to elucidate the effects of HIV and its treatment on bone health. PUBLIC HEALTH RELEVANCE: Older minority women comprise a growing proportion of HIV-infected adults in the United States. This proposal seeks continued support to study "Osteoporosis in HIV-infected Postmenopausal Women" (R01 AI065200). During the current funding period, we documented lower bone density (BMD), higher prevalence of certain non-vertebral fractures, higher bone turnover, higher rates of bone loss in HIV+ women than HIV- women, and indirect evidence of increased osteoclast numbers particularly in HIV+ women on ritonavir-boosted protease inhibitor (RTV-PI) regimens. In addition, vitamin D insufficiency and deficiency were extremely common, affecting 76% of the subjects and were associated with lower current CD4 counts. In the renewal, we will recruit additional HIV+ subjects in order to have greater power to investigate BMD, biochemical and bone cell differences among different antiretroviral therapy (ART) subgroups. Specifically, we will test the hypotheses that certain ART regimens are associated with higher bone turnover, circulating osteoclast and osteoblast precursors, and rates of bone loss; that repletion of vitamin D in D insufficient and deficient HIV+ postmenopausal women will be associated with a decline in bone turnover and rates of bone loss and may influence indices of immune function; that initiation of ART converts the low bone turnover state of untreated HIV infection to a high turnover state associated with detectable bone loss; and that tenofovir disoproxil fumarate (TDF)-based regimens that include RTV-PIs or efavirenz, a cytochrome P450 inducer, will differentially affect BMD, mineral metabolism, bone cells and turnover. We will test these hypotheses utilizing established state-of-the-art biochemical assays and novel technologies, such as high-resolution peripheral quantitative CT (HR- pQCT) and quantification and characterization of circulating osteoblast and osteoclast precursors, which will permit assessment of bone microarchitecture and remodeling activity without the requirement for a bone biopsy.
描述(由申请人提供):绝经后HIV+女性骨折的风险增加,容易受到D缺乏、HIV感染和与ART相关的骨丢失对骨骼强度的不利影响。老年少数族裔妇女感染艾滋病毒的比例越来越高,感染艾滋病毒的人口老龄化,因此必须阐明艾滋病毒及其治疗对骨骼健康的影响。 公共卫生相关性:老年少数族裔妇女在美国感染艾滋病毒的成年人中所占比例越来越大。该提案寻求继续支持研究“感染艾滋病毒的绝经后妇女中的骨质疏松症”(R01AI065200)。在目前的资助期间,我们记录了HIV+妇女比HIV妇女更低的骨密度(BMD)、更高的某些非脊椎骨折的患病率、更高的骨转换、更高的骨丢失率,以及间接证据表明破骨细胞数量增加,特别是在服用利托那韦促进的蛋白酶抑制剂(RTV-PI)方案的HIV+妇女中。此外,维生素D缺乏和缺乏是非常普遍的,影响到76%的受试者,并与目前较低的CD4计数有关。在更新中,我们将招募更多的HIV+受试者,以便有更大的权力调查不同抗逆转录病毒治疗(ART)亚组之间的骨密度、生化和骨细胞差异。具体地说,我们将测试这些假设,即某些ART方案与更高的骨周转率、循环中的破骨细胞和成骨细胞前体以及骨丢失率有关;D缺乏和缺乏HIV+绝经后妇女的维生素D补充将与骨周转和骨丢失率下降相关,并可能影响免疫功能的指标;启动ART可将未经治疗的HIV感染的低骨转换状态转变为与可检测到的骨丢失相关的高周转状态;以替诺福韦为基础的疗法,包括RTV-PI或细胞色素P450诱导剂efavirenz,将对BMD、矿物质代谢、骨细胞和周转产生不同的影响。我们将利用已建立的最先进的生化分析和新技术来验证这些假设,例如高分辨率外周定量CT(HR-pQCT)和循环成骨细胞和破骨细胞前体的定量和表征,这将允许在不需要骨活检的情况下评估骨微结构和重塑活动。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth J Shane其他文献

Elizabeth J Shane的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth J Shane', 18)}}的其他基金

Phase 2b Study of Denosumab to Prevent Bone Loss in Idiopathic Osteoporosis in Premenopausal Women Treated with Teriparatide
狄诺塞麦 (Denosumab) 预防接受特立帕肽治疗的绝经前妇女特发性骨质疏松症骨丢失的 2b 期研究
  • 批准号:
    9282269
  • 财政年份:
    2016
  • 资助金额:
    $ 72.69万
  • 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
  • 批准号:
    8414605
  • 财政年份:
    2011
  • 资助金额:
    $ 72.69万
  • 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
  • 批准号:
    8717112
  • 财政年份:
    2011
  • 资助金额:
    $ 72.69万
  • 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
  • 批准号:
    8542495
  • 财政年份:
    2011
  • 资助金额:
    $ 72.69万
  • 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
  • 批准号:
    8020203
  • 财政年份:
    2011
  • 资助金额:
    $ 72.69万
  • 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
  • 批准号:
    8913676
  • 财政年份:
    2011
  • 资助金额:
    $ 72.69万
  • 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
  • 批准号:
    8333235
  • 财政年份:
    2011
  • 资助金额:
    $ 72.69万
  • 项目类别:
Osteoporosis in HIV Infected Postmenopausal Women
感染艾滋病毒的绝经后妇女的骨质疏松症
  • 批准号:
    8100411
  • 财政年份:
    2010
  • 资助金额:
    $ 72.69万
  • 项目类别:
Osteoporosis in HIV Infected Postmenopausal Women
感染艾滋病毒的绝经后妇女的骨质疏松症
  • 批准号:
    8494520
  • 财政年份:
    2010
  • 资助金额:
    $ 72.69万
  • 项目类别:
Osteoporosis in HIV Infected Postmenopausal Women
感染艾滋病毒的绝经后妇女的骨质疏松症
  • 批准号:
    8011797
  • 财政年份:
    2010
  • 资助金额:
    $ 72.69万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.69万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了